How should we best target the biology of ER PR HER2 negative breast cancer?

被引：0
|
作者：
Tutt, A. N. J. [1 ]
Reis-Filho, J. S. [2 ]
机构：
[1] Kings Coll London, Breakthrough Breast Canc Res Unit, London WC2R 2LS, England
[2] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(08)70703-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：166 / 166
页数：1
相关论文
共 50 条
  • [41] Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival
    Onitilo, Adedayo
    Engel, Jessica
    Greenlee, Robert
    Mukesh, Bickol
    CLINICAL MEDICINE & RESEARCH, 2009, 7 (1-2) : 4 - 13
  • [42] Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
    Jiaxin, Chen
    Jinmei, Zhou
    Huiqiang, Zhang
    Xuexue, Wu
    Xiaobo, Wang
    Shaohua, Zhang
    Yanhong, Tai
    Zefei, Jiang
    Tao, Wang
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [43] Breast cancer subtypes based on ER/PR and HER2 expression: A population-based experience
    Onitilo, A. A.
    Engel, J.
    Greenlee, R. T.
    Mukesh, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Looking beyond the ER, PR, and HER2: what's new in the ARsenal for combating breast cancer?
    Srivastava, Tryambak Pratap
    Dhar, Ruby
    Karmakar, Subhradip
    REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2025, 23 (01)
  • [45] Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California
    Parise, Carol
    Caggiano, Vincent
    CANCER EPIDEMIOLOGY, 2014, 38 (05) : 556 - 562
  • [46] Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer
    Chen, Chih-Jung
    Chen, Ting-Hao
    Lei, Jason
    Liang, Ji-An
    Yang, Po-Sheng
    Huang, Chiun-Sheng
    Hsieh, Chia-Ming
    Tseng, Ling-Ming
    Liu, Liang-Chih
    Cheng, Skye Hung-Chen
    Shih, Kuan-Hui
    BIOSCIENCE REPORTS, 2022, 42 (01)
  • [47] Limitations in assessment of ER, PR, and HER2 status of breast cancer patients: Yangon experience.
    Mon, Yin Yin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Female Breast Cancer Status According to ER, PR and HER2 Expression: A Population Based Analysis
    Caldarella, Adele
    Crocetti, Emanuele
    Bianchi, Simonetta
    Vezzosi, Vania
    Urso, Carmelo
    Biancalani, Mauro
    Zappa, Marco
    PATHOLOGY & ONCOLOGY RESEARCH, 2011, 17 (03) : 753 - 758
  • [49] Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results
    van Es, Suzanne C.
    van der Vegt, Bert
    Bensch, Frederike
    Gerritse, Sophie
    van Heiden, Erik J.
    Boon, Eline
    Angus, Lindsay
    Overbosch, Jelle
    van Oordt, Catharina W. Menke-van der Houven
    Verheul, Henk M.
    van Herpen, Carla M. L.
    Jager, Agnes
    Oosting, Sjoukje F.
    de Vries, Elisabeth G. E.
    Schroder, Carolina P.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2019, 43 (10) : 1355 - 1360
  • [50] ER and PR Immunohistochemistry and HER2 FISH versus Oncotype DX: Implications for Breast Cancer Treatment
    Park, MiHee M.
    Ebel, Joshua J.
    Zhao, Weiquiang
    Zynger, Debra L.
    BREAST JOURNAL, 2014, 20 (01): : 37 - 45
12345